{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:23:33Z","timestamp":1788989013272,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeutic algorithm of RCC patients and the survival outcomes have changed dramatically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Herein we present a retrospective study of the patients treated in our Department with an antiangiogenic agent -Axitinib, a tyrosine kinase inhibitor- as a third or further line treatment. Statistical analysis was performed with SPSS, including the available clinicopathological data of the patients included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Axitinib was found to be active in patients who received this treatment beyond second line. The toxicity profile of this regimen did not reveal any unknown adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our real world data reflect that axitinib is a safe and effective option, even beyond the second line.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-020-00618-1","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T04:04:32Z","timestamp":1591070672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Axitinib as a third or further line of treatment in renal cancer: a single institution experience"],"prefix":"10.1186","volume":"20","author":[{"given":"G.","family":"Tsironis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Liontos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kyriazoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Koutsoukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tsiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kaparelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Skafida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fontara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"issue":"1","key":"618_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.critrevonc.2014.08.005","volume":"93","author":"F Zagouri","year":"2015","unstructured":"Zagouri F, Peroukidis S, Tzannis K, Kouloulias V, Bamias A, Hellenic Genito-Urinary Cancer G. Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: a systematic review and critical evaluation by the Hellenic Genito-urinary Cancer group (HGUCG). Crit Rev Oncol Hematol. 2015;93(1):36\u201349.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"618_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1634\/theoncologist.2016-0435","volume":"22","author":"A Bamias","year":"2017","unstructured":"Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, Tzannis K, Kontovinis L, Stravodimos K, Papatsoris A, et al. Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation. Oncologist. 2017;22(6):667\u201379.","journal-title":"Oncologist"},{"issue":"23","key":"618_CR3","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMra043172","volume":"353","author":"HT Cohen","year":"2005","unstructured":"Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477\u201390.","journal-title":"N Engl J Med"},{"issue":"2","key":"618_CR4","doi-asserted-by":"publisher","first-page":"F145","DOI":"10.1152\/ajprenal.00480.2016","volume":"313","author":"R Shingarev","year":"2017","unstructured":"Shingarev R, Jaimes EA. Renal cell carcinoma: new insights and challenges for a clinician scientist. Am J Physiol Renal Physiol. 2017;313(2):F145\u201354.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"618_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115\u201324.","journal-title":"N Engl J Med"},{"issue":"6","key":"618_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"618_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125\u201334.","journal-title":"N Engl J Med"},{"issue":"9605","key":"618_CR8","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103\u201311.","journal-title":"Lancet"},{"issue":"19","key":"618_CR9","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, et al. Cabozantinib versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814\u201323.","journal-title":"N Engl J Med"},{"issue":"9637","key":"618_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449\u201356.","journal-title":"Lancet"},{"issue":"22","key":"618_CR11","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271\u201381.","journal-title":"N Engl J Med"},{"issue":"15","key":"618_CR12","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473\u201382.","journal-title":"Lancet Oncol"},{"issue":"19","key":"618_CR13","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"key":"618_CR14","doi-asserted-by":"publisher","first-page":"101966","DOI":"10.1016\/j.ctrv.2020.101966","volume":"84","author":"S Fogli","year":"2020","unstructured":"Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R, Rini BI, Schmidinger M. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev. 2020;84:101966.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"618_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11912-020-0892-1","volume":"22","author":"S Gulati","year":"2020","unstructured":"Gulati S, Vaishampayan U. Current state of systemic therapies for advanced renal cell carcinoma. Curr Oncol Rep. 2020;22(3):26.","journal-title":"Curr Oncol Rep"},{"key":"618_CR16","doi-asserted-by":"crossref","unstructured":"Angulo JC, Shapiro O. The Changing Therapeutic Landscape of Metastatic Renal Cancer. Cancers (Basel). 2019;11(9):1227.","DOI":"10.3390\/cancers11091227"},{"issue":"5","key":"618_CR17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"B Ljungberg","year":"2015","unstructured":"Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913\u201324.","journal-title":"Eur Urol"},{"issue":"3","key":"618_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","volume":"15","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(3):286\u201396.","journal-title":"Lancet Oncol"},{"issue":"3","key":"618_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejca.2011.11.027","volume":"48","author":"E Calvo","year":"2012","unstructured":"Calvo E, Escudier B, Motzer RJ, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Ravaud A, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer. 2012;48(3):333\u20139.","journal-title":"Eur J Cancer"},{"issue":"9807","key":"618_CR20","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931\u20139.","journal-title":"Lancet"},{"issue":"6","key":"618_CR21","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","volume":"14","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552\u201362.","journal-title":"Lancet Oncol"},{"issue":"4","key":"618_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/iju.13314","volume":"24","author":"SK Pal","year":"2017","unstructured":"Pal SK, Signorovitch JE, Li N, Zichlin ML, Liu Z, Ghate SR, Perez JR, Vogelzang NJ. Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the USA. Int J Urol. 2017;24(4):272\u20138.","journal-title":"Int J Urol"},{"issue":"6","key":"618_CR23","first-page":"723","volume":"22","author":"E MacLean","year":"2016","unstructured":"MacLean E, Cisar L, Mehle K, Eremina D, Quigley JM. Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets. J Manag Care Spec Pharm. 2016;22(6):723\u2013732u.","journal-title":"J Manag Care Spec Pharm"},{"issue":"15","key":"618_CR24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/fon-2016-0566","volume":"13","author":"TE Hutson","year":"2017","unstructured":"Hutson TE, Jiao X, Wilson T, Cisar L, MacLean EA. Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers. Future Oncol. 2017;13(15):1323\u201332.","journal-title":"Future Oncol"},{"issue":"2","key":"618_CR25","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1016\/j.clgc.2014.08.011","volume":"13","author":"CE Kyriakopoulos","year":"2015","unstructured":"Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, et al. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Clin Genitourin Cancer. 2015;13(2):e79\u201385.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"618_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11523-017-0487-4","volume":"12","author":"BI Rini","year":"2017","unstructured":"Rini BI, Gruenwald V, Jonasch E, Fishman MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair AH, et al. Long-term duration of first-line Axitinib treatment in advanced renal cell carcinoma. Target Oncol. 2017;12(3):333\u201340.","journal-title":"Target Oncol"},{"issue":"3","key":"618_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clgc.2013.04.001","volume":"11","author":"AM Molina","year":"2013","unstructured":"Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, Patil S, Motzer RJ. Long-term response to sunitinib therapy for metastatic renal cell carcinoma. Clin Genitourin Cancer. 2013;11(3):297\u2013302.","journal-title":"Clin Genitourin Cancer"},{"key":"618_CR28","doi-asserted-by":"publisher","first-page":"7309","DOI":"10.2147\/OTT.S111137","volume":"9","author":"O Smaletz","year":"2016","unstructured":"Smaletz O, Chacon M, de Oliveira KL, de Carvalho Rocha DR, Cardoso FC. Long-term benefit of sunitinib in patients with metastatic renal cell carcinoma in Latin America: retrospective analysis of patient clinical characteristics. Onco Targets Ther. 2016;9:7309\u201314.","journal-title":"Onco Targets Ther"},{"key":"618_CR29","unstructured":"Tannir NM, Figlin RA, Gore ME, Michaelson MD, Motzer RJ, Porta C, Rini BI, Hoang C, Lin X, Escudier B. Long-term response to Sunitinib treatment in metastatic renal cell carcinoma: a pooled analysis of clinical trials. Clin Genitourin Cancer. 2017;S1558-7673(17)30171\u20134."},{"key":"618_CR30","doi-asserted-by":"crossref","unstructured":"Park J, Jiao X, Ghate S, Wilson T, Ahmad QI, Vogelzang NJ. Predictors of long-term response with Pazopanib in patients with advanced renal-cell carcinoma. Clin Genitourin Cancer. 2018;16(4):293\u20137.","DOI":"10.1016\/j.clgc.2018.03.005"},{"issue":"8","key":"618_CR31","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.21873\/anticanres.12807","volume":"38","author":"A Sbrana","year":"2018","unstructured":"Sbrana A, Biasco E, Paolieri F, Palesandro E, Caserta C, Iacovelli R, Detti B, Santini D, Mosca A, Morelli F, et al. Long-term response to first-line Pazopanib therapy in mRCC patients: a multicenter Italian experience. Anticancer Res. 2018;38(8):4913\u20138.","journal-title":"Anticancer Res"},{"issue":"34","key":"618_CR32","doi-asserted-by":"publisher","first-page":"36870","DOI":"10.18632\/oncotarget.4874","volume":"6","author":"HL Zhang","year":"2015","unstructured":"Zhang HL, Qin XJ, Wang HK, Gu WJ, Ma CG, Shi GH, Zhou LP, Ye DW. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study. Oncotarget. 2015;6(34):36870\u201383.","journal-title":"Oncotarget"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00618-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-020-00618-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-020-00618-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T20:06:49Z","timestamp":1622578009000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-020-00618-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["618"],"URL":"https:\/\/doi.org\/10.1186\/s12894-020-00618-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.21472\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.21472\/v2","asserted-by":"object"}]},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]},"assertion":[{"value":"12 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ethics committee of General Hospital Alexandra approved the study and patients have signed informed consent for the analysis and publication of their data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MAD: Jansen, Celgene, Takeda, Amgen, Genesis Pharma, BMS.AM: Roche, BMS, Astra Zeneca, MSD.ML: Roche, Astra Zeneca, Astellas, MSD, Ipsen, Jansen, BMS, Spouse is Pfizer emplyee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}